WASHINGTON, D.C.—“Rheumatic manifestations are [often] the initial presentation of a systemic disease, but they can [also] occur during the course of the disorder,” said Joseph Markenson, MD, speaking in the ACR/ARHP Annual Meeting talk, Rheumatic Manifestations of Endocrine Disease, during the ACR Review Course. Dr. Markenson is professor of clinical medicine and a rheumatologist at Weill…
Combining Humanities, Clinical Care Essential to Providing Quality Healthcare
WASHINGTON, D.C.—Paulette Hahn, MD, associate professor of medicine specializing in rheumatology at the University of Florida (UF), said she once treated a patient named Monica, a UF undergraduate who had severe inflammatory muscle disease and severe lung disease. The patient’s disease was under control for the time being, but Monica knew she could take a…
When Interstitial Lung Disease and Connective Tissue Disorder Intersect in Rheumatology Patients
SAN FRANCISCO—Interstitial lung disease (ILD) represents a heterogeneous group of disorders characterized by inflammation or fibrosis of the lungs. The disorders are also associated with a spectrum of connective tissue diseases (CTDs). ILD is a common manifestation of CTDs, such as scleroderma, poly-/dermatomyositis and rheumatoid arthritis—and is a leading cause of morbidity and mortality in…
The ACR Teams with National Bone Health Alliance to Increase Focus on Osteoporosis, Bone Disease
Bone health in general, and osteoporosis in particular, is among the most common conditions seen in rheumatology practices. The ACR recently joined the National Bone Health Alliance (NBHA) to reach out to other stakeholders. “In 2004, the Surgeon General of the United States published a report on osteoporosis that discussed in depth the gaps in…
Baricitinib Effective for Treating Refractory Rheumatoid Arthritis
Soon, rheumatologists may have another drug to offer their patients with refractory rheumatoid arthritis (RRA) for whom effective and safe treatment remains challenging. A study published in the New England Journal of Medicine shows that patients with RRA treated with once-daily baricitinib in a 4 mg dose had a significant clinical improvement in symptoms of…
Tips, Resources to Help Rheumatologists Educate Patients on Biologics and Biosimilars
Rheumatologists are accustomed to educating patients about medications—but biologic medications require some additional time and discussion. “Biologics are inherently more complex [than other medications], and there are multiple issues to consider before initiating treatment,” says K. “Kwas” Huston, MD, The Center for Rheumatic Disease, Kansas City, Mo. “This includes the patient’s disease activity, prior medications…
ACR Recommends You Treat the Symptoms for Gout Patients
In 1982, my wife (also a rheumatologist) and I attended our first American Rheumatism Association (now the ACR) national meeting. After the meeting we stayed with a friend in a suburb of Boston, where we also had the opportunity to meet our hostess’ in-laws, a retired general practitioner and his wife. When her father-in-law shook…
Don’t Reach for Pills for Most Chronic Low Back Pain
(Reuters Health)—People should try non-drug treatment options like massage or stretching for most cases of chronic low back pain before choosing treatment with over-the-counter or prescription drugs, according to new guidelines from the American College of Physicians (ACP). If the pain began recently, the guidelines recommend superficial heat, massage, acupuncture or spinal manipulation. If patients…
Review Finds Increased Osteoarthritis Risk in Tactical Athletes
NEW YORK (Reuters Health)—Members of the military and firefighters are at increased risk of osteoarthritis (OA), a new systematic review shows. “Osteoarthritis is more common in people who are tactical athletes, people who are firefighters and military service members, than it is in the general population,” Dr. Kenneth Cameron of Keller Army Hospital in West…
Two U.S. Lawmakers Probe Marathon over $89,000 Drug Price
WASHINGTON (Reuters)—Two U.S. lawmakers have called on privately held Marathon Pharmaceuticals LLC to explain how it came to price its newly approved drug to treat Duchenne muscular dystrophy at $89,000 a year when patients have for decades been able to acquire it overseas for as little as $1,000. The drug, Emflaza, known generically as deflazacort,…
- « Previous Page
- 1
- …
- 410
- 411
- 412
- 413
- 414
- …
- 776
- Next Page »